So-Young International Inc. (SY) Q3 2024 Earnings Call Transcript Summary
So-Young International Inc. (SY) Q3 2024 Earnings Call Transcript Summary
Non-GAAP net income attributable to So-Young was RMB22.2 million, a significant increase of 133.1% year-over-year.The following is a summary of the So-Young International Inc. (SY) Q3 2024 Earnings Call Transcript:
以下是新氧國際公司（SY）2024年第三季度業績會議記錄總結：
Financial Performance:
財務表現：
So-Young International Inc. reported a Q3 2024 total revenue of RMB332 million, exceeding their guidance range.
Net income attributable to So-Young was RMB20.3 million, a year-over-year increase of 11.2%.
Non-GAAP net income attributable to So-Young was RMB22.2 million, a significant increase of 133.1% year-over-year.
Total revenues for the quarter were RMB371.8 million, with a year-over-year growth in sales of medical products and maintenance services by 18.7%.
新氧國際公司報告2024年第三季度總營業收入爲人民幣33200萬，超過他們的指導區間。
歸屬於新氧的淨利潤爲人民幣2030萬，同比增長11.2%。
非通用會計淨利潤歸屬於新氧爲人民幣2220萬，同比顯著增長133.1%。
本季度總營業收入爲人民幣37180萬，醫療產品和維護服務銷售同比增長18.7%。
Business Progress:
業務進展：
Expanded the chain of clinics to 17 from 8 in the previous quarter, improving market coverage and competitiveness.
Achieved positive operating cash flow in all new clinics, with four already profitable at the store level.
Customer retention rates maintained at 60% while overall customer satisfaction at clinics reached 4.98 out of 5.
Introduced and expanded high-end master injector team project, showing a 104% sequential revenue increase with high customer satisfaction.
Partnered strategically for upstream product development, notably with Lancy Group, leading to quick market adoption.
Planned expansion into five core cities and accelerating rollout of franchises.
Invested over RMB1 billion over three years in building upstream supply chain and expanding product offerings.
在前季度的基礎上，診所網絡從8家擴展至17家，提升市場覆蓋率和競爭力。
在所有新診所實現了正面的營運現金流，其中有四家門店已經盈利。
客戶保留率維持在60%，而診所整體客戶滿意度達到5分中的4.98。
推出並擴大高端主力注射團隊項目，顯示出104%的序貫營業收入增長和高客戶滿意度。
與Lancy Group等戰略合作進行上游產品開發，快速推動市場採納。
計劃擴張至五個核心城市，並加速連鎖加盟店的推出。
在三年內投資超過10億人民幣來構建上游供應鏈和拓展產品範圍。
Opportunities:
機會：
Continues expansion and integration efforts in the medical aesthetic market to capture larger market share and establish a solid profitability foundation.
Optimize cost and enhance service through the franchise model, supporting rapid growth and profitability at individual store levels.
繼續在醫療美容市場進行擴張與整合工作，以抓住更大市場份額並建立穩固的盈利基礎。
通過特許經營模式優化成本，提升服務，支持各門店實現快速增長和盈利能力。
Risks:
風險：
The market for medical aesthetic services is experiencing polarization, affecting consumer spending behaviors and preferences.
醫療美容服務市場正在出現兩極化，影響了消費者的消費行爲和偏好。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
